Reta weight loss results come from retatrutide, an investigational triple-agonist peptide. Learn what clinical trials show, dosing, side effects, and safety.
Reta weight loss refers to weight loss produced by retatrutide, an experimental once-weekly injection that activates three hormone receptors at the same time: GLP-1, GIP, and glucagon. In a Phase 2 trial, adults with obesity lost up to roughly 24% of their body weight after 48 weeks at the highest dose. Retatrutide is not FDA-approved for human use and is currently available only through clinical trials.
What Is Reta for Weight Loss?
"Reta" is shorthand for retatrutide, a triple-agonist drug developed by Eli Lilly. It is given as a once-weekly subcutaneous injection and is being studied in the Phase 3 TRIUMPH program. The question "what is reta for weight loss" usually comes down to this: it is a GLP-1 class medicine in development, not a marketed product.
Unlike semaglutide, which targets GLP-1 only, retatrutide adds GIP and glucagon receptor activity. That third pathway is what separates it from most weight loss peptides reta users read about online.
As of 2025, retatrutide has no FDA approval and no brand name. Any product sold as a reta weight loss pill or reta weight loss injection outside a trial is unregulated and unverified.
Does Reta Burn Fat? How the Drug Actually Works
Retatrutide does not burn fat by itself. Most of its effect comes from reducing appetite and slowing stomach emptying, which lowers calorie intake.
Glucagon receptor activation may add a second effect by increasing energy expenditure and fat oxidation. Early data suggest that combining the three pathways produces more weight loss than GLP-1-only drugs.
Appetite changes usually appear within the first few weeks, but the full effect builds over months as the dose increases.
Body composition matters here: some of the weight lost is lean mass rather than fat. Clinicians generally recommend adequate protein and resistance training for anyone losing weight rapidly on a GLP-1 based drug.
Reta Weight Loss Results in Clinical Trials
The largest published dataset comes from a Phase 2 trial of 338 adults with obesity or overweight plus a weight-related condition, reported in the New England Journal of Medicine in 2023. Participants received weekly injections for 48 weeks.
| Weekly dose | Average weight loss at 48 weeks |
|---|---|
| Placebo | About 2% |
| 1 mg | About 9% |
| 4 mg | About 17% |
| 8 mg | About 23% |
| 12 mg | About 24% |
These are averages from a single Phase 2 trial, not guarantees. Phase 3 studies are still running, and their results will determine whether the FDA approves retatrutide and at which doses.
Injection vs. Pills: What Forms of Reta Exist
| Format | Status | What to know |
|---|---|---|
| Once-weekly injection | Investigational | Used only in clinical trials; not legally for sale |
| Oral pills or capsules | None exist | Products marketed as reta weight loss pills are not retatrutide |
| Research-grade powder | Sold as a "research chemical" | Not for human use; no sterility, purity, or dose oversight |
Many people start searching for peptides reta for weight loss after seeing them listed on vendor sites. Those listings typically ship a lyophilized powder with no independent testing, and the labeled dose may be inaccurate.
If you are comparing options, it helps to read is reta or tirz better for weight loss before assuming the newer drug is stronger. Tirzepatide is approved and available by prescription; retatrutide is not.
Reta Weight Loss Dosing and Access
In trials, retatrutide started at 1 mg or 2 mg weekly and increased roughly every four weeks to reach 8 mg or 12 mg. Slow escalation is used to limit nausea and other digestive side effects.
There is no legal way to buy retatrutide in the United States today. The only route is enrollment in a clinical trial listed on ClinicalTrials.gov or run through a research site.
Side Effects and Safety
- Nausea, vomiting, diarrhea, and constipation are the most common complaints, especially during dose increases.
- Heart rate increases of a few beats per minute were reported in trials.
- Gallbladder events and injection-site reactions can occur.
- GLP-1 drugs carry a boxed warning about thyroid C-cell tumors seen in rodents; the human risk is unknown.
- This drug class is not recommended during pregnancy or breastfeeding.
Serious but uncommon risks include pancreatitis and gallbladder disease, so severe abdominal pain is a reason to stop and seek care. Because retatrutide is unapproved, long-term safety data are limited.
Anyone considering retatrutide should talk with a healthcare professional about approved alternatives first.
Other Peptides People Compare With Reta
Reta is not the only peptide discussed for fat loss. Questions like does bpc-157 help with weight loss come up often, though BPC-157 is studied mainly for tissue repair rather than fat reduction.
Growth-hormone secretagogues such as cjc 1295 ipamorelin for weight loss work through a completely different pathway and have much weaker evidence for meaningful fat loss. Similarly, aod 9604 peptide for weight loss has only small studies behind it, and does kpv help with weight loss is largely unanswered in human data.
None of these peptides is FDA-approved for weight loss. Retatrutide has the strongest trial data of the group, and even retatrutide remains experimental.
Frequently Asked Questions
Is reta approved for weight loss in the US?
No. Retatrutide is an investigational drug and is not FDA-approved for any use, so it is available only through clinical trials. Approved prescription options include semaglutide (Wegovy) and tirzepatide (Zepbound).
How much weight can you lose on reta?
In a 48-week Phase 2 trial, participants on 12 mg weekly lost about 24% of their body weight on average, while those on 8 mg lost about 23%. Individual results vary, and Phase 3 data are still pending.
Does reta burn fat or just suppress appetite?
It does both, but indirectly. Retatrutide mainly lowers appetite and calorie intake through GLP-1 and GIP activity, while glucagon receptor activation may raise energy expenditure. Fat loss follows the resulting calorie deficit.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.